These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 39203969)

  • 1. Comparison of Post-Vaccination Cellular Immune Response in Patients with Common Variable Immune Deficiency.
    Kostinova AM; Latysheva EA; Kostinov MP; Akhmatova NK; Skhodova SA; Vlasenko AE; Cherdantsev AP; Soloveva IL; Khrapunova IA; Loktionova MN; Khromova EA; Poddubikov AA
    Vaccines (Basel); 2024 Jul; 12(8):. PubMed ID: 39203969
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expression of Toll-like Receptors on the Immune Cells in Patients with Common Variable Immune Deficiency after Different Schemes of Influenza Vaccination.
    Kostinova AM; Latysheva EA; Akhmatova NK; Vlasenko AE; Skhodova SA; Khromova EA; Linok AV; Poddubikov AA; Latysheva TV; Kostinov MP
    Viruses; 2023 Oct; 15(10):. PubMed ID: 37896869
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Assessment of Immunogenicity of Adjuvanted Quadrivalent Inactivated Influenza Vaccine in Healthy People and Patients With Common Variable Immune Deficiency.
    Kostinova AM; Akhmatova NK; Latysheva EA; Dagil YA; Klimova SV; Vlasenko AE; Khromova EA; Latysheva TV; Kostinov MP
    Front Immunol; 2020; 11():1876. PubMed ID: 32973775
    [No Abstract]   [Full Text] [Related]  

  • 4. Cellular and humoral influenza-specific immune response upon vaccination in patients with common variable immunodeficiency and unclassified antibody deficiency.
    Hanitsch LG; Löbel M; Mieves JF; Bauer S; Babel N; Schweiger B; Wittke K; Grabowski P; Volk HD; Scheibenbogen C
    Vaccine; 2016 May; 34(21):2417-2423. PubMed ID: 27055021
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immune Responses 6 Months After mRNA-1273 COVID-19 Vaccination and the Effect of a Third Vaccination in Patients with Inborn Errors of Immunity.
    van Leeuwen LPM; Grobben M; GeurtsvanKessel CH; Ellerbroek PM; de Bree GJ; Potjewijd J; Rutgers A; Jolink H; van de Veerdonk FL; van Gils MJ; de Vries RD; Dalm VASH;
    J Clin Immunol; 2023 Aug; 43(6):1104-1117. PubMed ID: 37231290
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunogenicity of the mRNA-1273 COVID-19 vaccine in adult patients with inborn errors of immunity.
    van Leeuwen LPM; GeurtsvanKessel CH; Ellerbroek PM; de Bree GJ; Potjewijd J; Rutgers A; Jolink H; van de Veerdonk F; van Gorp ECM; de Wilt F; Bogers S; Gommers L; Geers D; Bruns AHW; Leavis HL; van Haga JW; Lemkes BA; van der Veen A; de Kruijf-Bazen SFJ; van Paassen P; de Leeuw K; van de Ven AAJM; Verbeek-Menken PH; van Wengen A; Arend SM; Ruten-Budde AJ; van der Ent MW; van Hagen PM; Sanders RW; Grobben M; van der Straten K; Burger JA; Poniman M; Nierkens S; van Gils MJ; de Vries RD; Dalm VASH
    J Allergy Clin Immunol; 2022 Jun; 149(6):1949-1957. PubMed ID: 35421449
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunogenicity and Safety of the Quadrivalent Adjuvant Subunit Influenza Vaccine in Seropositive and Seronegative Healthy People and Patients with Common Variable Immunodeficiency.
    Kostinov MP; Latysheva EA; Kostinova AM; Akhmatova NK; Latysheva TV; Vlasenko AE; Dagil YA; Khromova EA; Polichshuk VB
    Vaccines (Basel); 2020 Nov; 8(4):. PubMed ID: 33147763
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impaired Memory B-Cell Response to Influenza Immunization in Patients With Common Variable Immunodeficiency (CVID).
    Zhan W; Hatchette T; Yue F; Liu J; Song H; Zhao H; Betschel S; Ostrowski M
    Pathog Immun; 2021; 6(2):105-118. PubMed ID: 34988341
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunogenicity of Anti-SARS-CoV-2 Vaccines in Common Variable Immunodeficiency.
    Arroyo-Sánchez D; Cabrera-Marante O; Laguna-Goya R; Almendro-Vázquez P; Carretero O; Gil-Etayo FJ; Suàrez-Fernández P; Pérez-Romero P; Rodríguez de Frías E; Serrano A; Allende LM; Pleguezuelo D; Paz-Artal E
    J Clin Immunol; 2022 Feb; 42(2):240-252. PubMed ID: 34787773
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy, immunogenicity, and safety evaluation of an MF59-adjuvanted quadrivalent influenza virus vaccine compared with non-adjuvanted influenza vaccine in children: a multicentre, randomised controlled, observer-blinded, phase 3 trial.
    Vesikari T; Kirstein J; Devota Go G; Leav B; Ruzycky ME; Isakov L; de Bruijn M; Oberye J; Heijnen E
    Lancet Respir Med; 2018 May; 6(5):345-356. PubMed ID: 29631857
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preserved Cellular Immunity Upon Influenza Vaccination in Most Patients with Common Variable Immunodeficiency.
    Friedmann D; Goldacker S; Peter HH; Warnatz K
    J Allergy Clin Immunol Pract; 2020; 8(7):2332-2340.e5. PubMed ID: 32330665
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and immunogenicity of concomitant administration of COVID-19 vaccines (ChAdOx1 or BNT162b2) with seasonal influenza vaccines in adults in the UK (ComFluCOV): a multicentre, randomised, controlled, phase 4 trial.
    Lazarus R; Baos S; Cappel-Porter H; Carson-Stevens A; Clout M; Culliford L; Emmett SR; Garstang J; Gbadamoshi L; Hallis B; Harris RA; Hutton D; Jacobsen N; Joyce K; Kaminski R; Libri V; Middleditch A; McCullagh L; Moran E; Phillipson A; Price E; Ryan J; Thirard R; Todd R; Snape MD; Tucker D; Williams RL; Nguyen-Van-Tam JS; Finn A; Rogers CA;
    Lancet; 2021 Dec; 398(10318):2277-2287. PubMed ID: 34774197
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Immune Response to SARS-CoV-2 Vaccination: Insights Learned From Adult Patients With Common Variable Immune Deficiency.
    Quinti I; Locatelli F; Carsetti R
    Front Immunol; 2021; 12():815404. PubMed ID: 35126372
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunization with trivalent inactivated influenza vaccine in partially immunized toddlers.
    Englund JA; Walter EB; Gbadebo A; Monto AS; Zhu Y; Neuzil KM
    Pediatrics; 2006 Sep; 118(3):e579-85. PubMed ID: 16950949
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cell-mediated immune responses to inactivated trivalent influenza-vaccination are decreased in patients with common variable immunodeficiency.
    van Assen S; de Haan A; Holvast A; Horst G; Gorter L; Westra J; Kallenberg CG; Telgt DS; Palache AM; Giezeman KM; Bijl M
    Clin Immunol; 2011 Nov; 141(2):161-8. PubMed ID: 21889412
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunogenicity of COVID-19 booster vaccination in IEI patients and their one year clinical follow-up after start of the COVID-19 vaccination program.
    van Leeuwen LPM; Grobben M; GeurtsvanKessel CH; Ellerbroek PM; de Bree GJ; Potjewijd J; Rutgers A; Jolink H; van de Veerdonk FL; van Gils MJ; de Vries RD; Dalm VASH;
    Front Immunol; 2024; 15():1390022. PubMed ID: 38698851
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety, immunogenicity, and efficacy of a COVID-19 vaccine (NVX-CoV2373) co-administered with seasonal influenza vaccines: an exploratory substudy of a randomised, observer-blinded, placebo-controlled, phase 3 trial.
    Toback S; Galiza E; Cosgrove C; Galloway J; Goodman AL; Swift PA; Rajaram S; Graves-Jones A; Edelman J; Burns F; Minassian AM; Cho I; Kumar L; Plested JS; Rivers EJ; Robertson A; Dubovsky F; Glenn G; Heath PT;
    Lancet Respir Med; 2022 Feb; 10(2):167-179. PubMed ID: 34800364
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A 1-year follow-on study from a randomised, head-to-head, multicentre, open-label study of two pandemic influenza vaccines in children.
    de Whalley P; Walker W; Snape MD; Oeser C; Casey M; Moulsdale P; Harrill C; Andrews N; Hoschler K; Thompson B; Jones C; Chalk J; Kerridge S; Tomlinson R; Heath PT; Finn A; Faust S; Miller E; Pollard AJ
    Health Technol Assess; 2011 Dec; 15(45):v-vi, xi-xiii, 1-128. PubMed ID: 22257497
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term persistence of humoral and cellular immune responses induced by an AS03A-adjuvanted H1N1 2009 influenza vaccine: an open-label, randomized study in adults aged 18-60 years and older.
    Van Damme P; Kafeja F; Bambure V; Hanon E; Moris P; Roman F; Gillard P
    Hum Vaccin Immunother; 2013 Jul; 9(7):1512-22. PubMed ID: 23571166
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An observer-blind, randomized, multi-center trial assessing long-term safety and immunogenicity of AS03-adjuvanted or unadjuvanted H1N1/2009 influenza vaccines in children 10-17 years of age.
    Poder A; Simurka P; Li P; Roy-Ghanta S; Vaughn D
    Vaccine; 2014 Feb; 32(9):1121-9. PubMed ID: 24252703
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.